Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication
Abstract
Forty-nine chronic psychiatric out-patients (ten were schizophrenic) with tardive dyskinesia (TD) were examined monthly for a mean of 40 weeks (range 1-59 months) after discontinuation of neuroleptic medication. Complete and persistent reversibility of TD was rare (2%), but many patients showed noticeable improvement in movements within the first year of discontinuation, which was sometimes interrupted by psychological relapse. Using three separate outcome measures and appropriate model-fitting techniques for each, we identified several predictors of improvement in TD, including an affective or schizoaffective psychiatric diagnosis, chronic (over 20 years) psychiatric illness, being employed, younger age, and increased neuroleptic dose before discontinuation. Consistent findings emerging from these analyses suggest that the type and history of psychiatric illness affect the course of TD.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Another study found that 92.8% of patients achieved a 50% reduction in TD symptoms 46 weeks after discontinuing on average 10 years of antipsychotic treatment.
“Another study found that 92.8% of patients achieved a 50% reduction in TD symptoms 46 weeks after discontinuing on average 10 years of antipsychotic treatment.77”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [77]
Cites
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090 · see citing works
Spitzer, R. L. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770300115013 · Cited by 6,946 · see citing works
Endicott, J. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770310043002 · Cited by 5,686 · see citing works
Spontaneous Involuntary Disorders of Movement
Owens, D. G. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290040052008 · Cited by 339 · see citing works
Changes in Prevalence, Severity, and Recovery in Tardive Dyskinesia With Age
Smith, J. M. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780250054006 · Cited by 310 · see citing works
Uhrbrand, L., & Faurbye, A. (1960) · Psychopharmacology · doi:10.1007/bf00441188 · Cited by 229 · see citing works
Crane, G. E. (1973) · The British Journal of Psychiatry · doi:10.1192/bjp.122.4.395 · Cited by 223 · see citing works
Tardive Dyskinesia—Reversible and Persistent
Jeste, D. V. (1979) · Archives of General Psychiatry · doi:10.1001/archpsyc.1979.01780050095012 · Cited by 199 · see citing works
Early Intervention, Time-limited, Targeted Pharmacotherapy of Schizophrenia
Carpenter, W. T., & Heinrichs, D. W. (1983) · Schizophrenia Bulletin · doi:10.1093/schbul/9.4.533 · Cited by 139 · see citing works
Tardive dyskinesia: are first signs reversible?
(1977) · American Journal of Psychiatry · doi:10.1176/ajp.134.1.84 · Cited by 114 · see citing works
Incidence of tardive dyskinesia: five-year data from a prospective study.
Kane, J. M., Woerner, M. G., Weinhold, P., Wegner, J. T., Kinon, B. J., & Borenstein, M. (1984) · PubMed · Cited by 111 · see citing works
Toxicity of Psychotropic Drugs
HUNTER, R. A., Earl, C., & Thornicroft, S. (1964) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591576405700835 · Cited by 99 · see citing works
Psychopharmacology: From Theory to Practice
Carroll, B. J. (1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.8.1005 · Cited by 94 · see citing works
Hershon, H. I., Kennedy, P. F., & McGuire, R. (1972) · The British Journal of Psychiatry · doi:10.1192/bjp.120.554.41 · Cited by 91 · see citing works
Clinical correlates of lateral ventricular enlargement in bipolar affective disorder
Pearlson, G. D., Garbacz, D. J., Tompkins, R., Ahn, H. S., Gutterman, D. F., Veroff, A. E., & DePaulo, J. R. (1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.2.253 · Cited by 84 · see citing works
The Significance of Brain Damage in Persistent Oral Dyskinesia
Edwards, H. (1970) · The British Journal of Psychiatry · doi:10.1192/bjp.116.532.271 · Cited by 75 · see citing works
PSYCHOTROPIC DRUGS AND DYSFUNCTIONS OF THE BASAL GANGLIA
Simpson, J. A. (1971) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.34.2.206-b · Cited by 74 · see citing works
Tardive Dyskinesia in Psychiatric Outpatients
Mukherjee, S. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290040064009 · Cited by 65 · see citing works
Glazer, W. M. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1984.01790170097011 · Cited by 64 · see citing works
Persistent Oral Dyskinesia in Female Mental Hospital Patients
Pryce, I. G., & Edwards, H. (1966) · The British Journal of Psychiatry · doi:10.1192/bjp.112.491.983 · Cited by 64 · see citing works
Differential diagnosis of tardive dyskinesia: an overview
Granacher, R. P. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.10.1288 · Cited by 62 · see citing works
Depression-Dependent Dyskinesias in Two Cases of Manic-Depressive Illness
Cutler, N. R., Post, R. M., Rey, A. C., & Bunney, W. E. (1981) · New England Journal of Medicine · doi:10.1056/nejm198104303041807 · Cited by 59 · see citing works
Tardive dyskinesia and the primary psychiatric diagnosis
YASSA, R., Nair, V. P., & Schwartz, G. J. (1984) · Psychosomatics · doi:10.1016/s0033-3182(84)73083-0 · Cited by 57 · see citing works
Depression as a risk factor in tardive dyskinesia.
Rush, M., Diamond, F., & Alpert, M. (1982) · PubMed · Cited by 57 · see citing works
Tardive dyskinesia and depressive illness.
Kl, D., Berger, P. A., & Hollister, L. E. (1976) · PubMed · Cited by 56 · see citing works
Heterogeneity of Tardive Dyskinesia
Glazer, W. M., Morgenstern, H., Niedzwiecki, D., & Hughes, J. (1988) · The British Journal of Psychiatry · doi:10.1192/bjp.152.2.253 · Cited by 47 · see citing works
Does Tardive Dyskinesia Exist?
Crow, T. J., Owens, D. G. C., Johnstone, E. C., Cross, A. J., & Owen, F. (2015) · Modern problems of pharmacopsychiatry/Modern trends in pharmacopsychiatry · doi:10.1159/000408495 · Cited by 38 · see citing works
Psychiatric Diagnosis and Risk for Tardive Dyskinesia
Hamra, B. J. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790030116019 · Cited by 35 · see citing works
Effects of drug withdrawal on tardive dyskinesia.
Crane, G. E., Ruiz, P., Kernohan, G. W., Wilson, W. J., & Royalty, N. (1969) · PubMed · Cited by 30 · see citing works
PERSISTENT DYSKINESIA AFTER LONG-TERM TREATMENT WITH NEUROLEPTICS IN JAPAN
Yagi, G., Ogita, K., Ohtsuka, N., Itoh, H., & Miura, S. (1976) · The Keio Journal of Medicine · doi:10.2302/kjm.25.27 · Cited by 29 · see citing works
THE ABILITY OF SCHIZOPHRENICS TO UNDERSTAND NORMAL, PSYCHOTIC AND PSEUDO-PSYCHOTIC SPEECH.
Honigfeld, G. (1963) · PubMed · Cited by 19 · see citing works
A TARDIVE DYSKINESIA CLINIC IN A MENTAL HEALTH CENTER
Glazer, W. M., & Moore, D. C. (1981) · Psychiatric Services · doi:10.1176/ps.32.8.572 · Cited by 18 · see citing works
Jm, S., Kucharski, L. T., Oswald, W., & Waterman, L. J. (1979) · PubMed · Cited by 18 · see citing works
The prevalence of presumed tardive dyskinesia in psychiatric inpatients and outpatients
Kane, J. M., Wegner, J. T., Stenzler, S., & Ramsey, P. P. (1980) · Psychopharmacology · doi:10.1007/bf00433090 · Cited by 17 · see citing works
An evaluation of the permanence of the "tardive dyskinesias".
Gw, P. (1968) · PubMed · Cited by 15 · see citing works
Depression as a predictor in the development of tardive dyskinesia.
YASSA, R., & Schwartz, G. (1984) · PubMed · Cited by 14 · see citing works
Clozapine and Tardive Dyskinesia
Singer, J. M. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790030117020 · Cited by 8 · see citing works
Tardive dyskinesia and psychopathology in chronic schizophrenia: A cross-sectional study
Karson, C. N., Jeste, D. V., & Bigelow, L. B. (1985) · Comprehensive Psychiatry · doi:10.1016/0010-440x(85)90096-3 · Cited by 8 · see citing works
Diagnosis of Tardive Dyskinesia
Goetz, C. G. (1985) · Springer eBooks · doi:10.1007/978-1-4684-8329-1_78 · Cited by 6 · see citing works
Flagged first, then by citations
2 of the 41 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Neuroleptic Withdrawal in Schizophrenic Patients
Gilbert, P. L. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150005001 · Cited by 434 · see citing works
Morgenstern, H. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820210057007 · Cited by 260 · see citing works
Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats
Andreassen, O. A., & Jørgensen, H. A. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00064-7 · Cited by 211 · see citing works
Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.
Caroff, S. N., Hurford, I., Lybrand, J., & Campbell, E. C. (2011) · Neurologic Clinics · doi:10.1016/j.ncl.2010.10.002 · Cited by 188 · see citing works
Treatment of Tardive Dyskinesia
Egan, M. F., Apud, J. A., & Wyatt, R. J. (1997) · Schizophrenia Bulletin · doi:10.1093/schbul/23.4.583 · Cited by 165 · see citing works
A Comprehensive Review of Tic Disorders in Children
Ueda, K., & BLACK, K. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112479 · Cited by 173 · see citing works
A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab017 · Cited by 157 · see citing works
Drug-Induced Extrapyramidal Syndromes
Caroff, S. N., & Campbell, E. C. (2016) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2016.04.003 · Cited by 139 · see citing works
Tardive Dyskinesia: Therapeutic Options for an Increasingly Common Disorder
Cloud, L. J., Zutshi, D., & Factor, S. A. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0222-5 · Cited by 115 · see citing works
“Studies of the natural history of TD have reported widely variable remission rates (1–62 % [43–46]) (Table 2) depending on patient age, psychiatric diagnosis, course of the psychiatric disorder, and duration of therapy [21, 46].”
BackgroundInfluentialSavitt, D., & Jankovic, J. J. (2018) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2018.02.005 · Cited by 106 · see citing works
Treatment Recommendations for Tardive Dyskinesia
Ricciardi, L., Pringsheim, T. M., Barnes, T. R. E., Martino, D., Gardner, D. M., Remington, G. J., Addington, D. E., Morgante, F., Poole, N. A., Carson, A. J., et al. (2019) · The Canadian Journal of Psychiatry · doi:10.1177/0706743719828968 · Cited by 104 · see citing works
Antipsychotic-induced extrapyramidal symptoms and their management
Dayalu, P., & Chou, K. L. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.9.1451 · Cited by 99 · see citing works
“If the antipsychotic agent can be discontinued, tardive dyskinesia generally improves [77,78] .”
Spectrum of tardive syndromes: clinical recognition and management
Bhidayasiri, R., & Boonyawairoj, S. (2010) · Postgraduate Medical Journal · doi:10.1136/pgmj.2010.103234 · Cited by 89 · see citing works
“Since, by definition, TD is an iatrogenic disorder, the best management is prevention. Patients should be advised of the inherent risk of developing TD before commencing drug therapy with neuroleptics. Once a TD is encountered, removal of the aetiologic agent should be seriously considered. Importantly, early detectio…”
BackgroundNiemann, N., & Jankovic, J. J. (2018) · Drugs · doi:10.1007/s40265-018-0874-x · Cited by 80 · see citing works
“During follow-up ranging from 1 to 59 months (mean * 40 weeks), 2% had complete resolution of TD, whereas 20% were noted to have significant improvement of symptoms [91].”
BackgroundPsychometric evaluation of a standardized and expanded Brief Psychiatric Rating Scale
Hafkenscheid, A. (1991) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1991.tb03147.x · Cited by 74 · see citing works
Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia
Vijayakumar, D., & Jankovic, J. J. (2016) · Drugs · doi:10.1007/s40265-016-0568-1 · Cited by 70 · see citing works
Zutshi, D., Factor, S., & Cloud, L. J. (2014) · PubMed Central · doi:10.7916/d85h7dzx · Cited by 67 · see citing works
Soares‐Weiser, K., & Rathbone, J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000459.pub2 · Cited by 60 · see citing works
Kinon, B. J., Jeste, D. V., Kollack‐Walker, S., Stauffer, V. L., & Liu‐Seifert, H. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.05.016 · Cited by 56 · see citing works
Anticholinergic medication for antipsychotic-induced tardive dyskinesia
Bergman, H., & Soares‐Weiser, K. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000204.pub2 · Cited by 55 · see citing works
DRUG-INDUCED MOVEMENT DISORDERS
Diederich, N. J., & Goetz, C. G. (1998) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70370-4 · Cited by 52 · see citing works
Wonodi, I., Adami, H. M., Cassady, S. L., Sherr, J. D., Avila, M. T., & Thaker, G. K. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000144888.43449.54 · Cited by 51 · see citing works
Bergman, H., Rathbone, J., Agarwal, V., & Soares‐Weiser, K. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000459.pub3 · Cited by 50 · see citing works
Cholinergic medication for antipsychotic-induced tardive dyskinesia
Tammenmaa-Aho, I., Asher, R., Soares‐Weiser, K., & Bergman, H. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000207.pub2 · Cited by 46 · see citing works
Thaakur, S. R., & Jyothi, B. (2007) · Journal of Neural Transmission · doi:10.1007/s00702-007-0744-2 · Cited by 44 · see citing works
“The most serious aspect of TD is that it may persist for months or years after drug withdrawal and in some patients it is irreversible (Jeste et al., 1979; Casey, 1985; Glazer et al., 1990 ).”
BackgroundVMAT2 inhibitors for the treatment of tardive dyskinesia
Scorr, L., & Factor, S. A. (2018) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2018.02.006 · Cited by 44 · see citing works
Ethical Concerns About Relapse Studies
Shamoo, A. E., & Keay, T. J. (1996) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s0963180100007180 · Cited by 41 · see citing works
Thakur, S., & Himabindhu, G. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0232-y · Cited by 41 · see citing works
“The most serious aspect of TD is that it may persist for months or years after drug withdrawal and in some patients it is irreversible (Jeste et al. 1979; Casey 1985a, b; Glazer et al. 1990) and the syndrome is a major clinical and ethical issue (APA 1992).”
BackgroundTardive Dyskinesia Outcomes: Clinical and Pharmacologic Correlates of Remission and Persistence
Cavallaro, R., Regazzetti, M. G., Mundo, E., Brancato, V., & Smeraldi, E. (1993) · Neuropsychopharmacology · doi:10.1038/npp.1993.26 · Cited by 40 · see citing works
Tardive Dyskinesia in Elderly Patients: An Update
Goldberg, R. J. (2002) · Journal of the American Medical Directors Association · doi:10.1016/s1525-8610(04)70458-2 · Cited by 40 · see citing works
Drug-Induced Movement Disorders
Claxton, K. L., Chen, J. J., & Swope, D. (2007) · Journal of Pharmacy Practice · doi:10.1177/0897190007310514 · Cited by 36 · see citing works
“For neuroleptic-induced TDk, the movements may improve in up to 50% of patients after withdrawal of the offending agent, but overall, complete and long-lasting resolution of TDk is uncommon.(58) Treatment for TDk varies and includes drug discontinuation, switching to or initiating an atypical antipsychotic,(59) discon…”
BackgroundDeprescribing antipsychotics: a guide for clinicians
Gupta, S., Cahill, J. D., & Miller, R. (2018) · BJPsych Advances · doi:10.1192/bja.2018.2 · Cited by 35 · see citing works
The mitochondrial toxin 3-nitropropionic acid aggravates reserpine-induced oral dyskinesia in rats
Calvente, P. R. V., Araujo, C. C. S., Bergamo, M., Abílio, V. C., D’Almeida, V., Ribeiro, R. D. A., & Frussa‐Filho, R. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00255-x · Cited by 35 · see citing works
“The most serious aspects of tardive dyskinesia are that it may persist for months or years after drug withdrawal and in some patients it is irreversible (Glazer et al., 1990).”
BackgroundManagement of Tardive Syndrome: Medications and Surgical Treatments
Factor, S. A. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00898-3 · Cited by 34 · see citing works
Vitamin E for antipsychotic-induced tardive dyskinesia
Soares‐Weiser, K., Maayan, N., & Bergman, H. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000209.pub3 · Cited by 34 · see citing works
Antipsychotic-induced tardive dyskinesia
Widschwendter, C. G., & Hofer, A. (2019) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000491 · Cited by 32 · see citing works
Andreassen, O. A., Ferrante, R. J., Beal, M. F., & Jørgensen, H. A. (1998) · Neuroscience · doi:10.1016/s0306-4522(98)00160-2 · Cited by 32 · see citing works
Benzodiazepines for antipsychotic-induced tardive dyskinesia
Bergman, H., Bhoopathi, P. S., & Soares‐Weiser, K. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000205.pub3 · Cited by 32 · see citing works
Larach, V. W., Zamboni, R., Mancini, H. R., Rueda, R. M., & Torres, R. G. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(97)00130-8 · Cited by 29 · see citing works
Miscellaneous treatments for antipsychotic-induced tardive dyskinesia
Soares‐Weiser, K., Rathbone, J., Ogawa, Y., Shinohara, K., & Bergman, H. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000208.pub2 · Cited by 29 · see citing works
The Prediction of Chronic Persistent Versus Intermittent Tardive Dyskinesia
Glazer, W. M., Morgenstern, H., & Doucette, J. T. (1991) · The British Journal of Psychiatry · doi:10.1192/bjp.158.6.822 · Cited by 28 · see citing works
Treating psychosis in movement disorder patients: a review
Borek, L. L., & Friedman, J. H. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.918955 · Cited by 25 · see citing works
Potentially adverse interactions between haloperidol and valerian
Corte, C. L. D., Fachinetto, R., Colle, D., Pereira, R. P., Ávila, D. S., Villarinho, J. G., Wagner, C., Pereira, M. E., Nogueira, C. W., Soares, F. A. A., et al. (2008) · Food and Chemical Toxicology · doi:10.1016/j.fct.2008.03.019 · Cited by 25 · see citing works
“This syndrome is characterized by involuntary orofacial movements and is often irreversible even after drug withdrawal (Gerlach and Casey, 1988; Glazer et al., 1990; Andreasen and Jorgensen, 2000).”
BackgroundBlood-Based Oxidation Markers in Medicated and Unmedicated Schizophrenia Patients: A Meta-Analysis
Goh, X. X., Tang, P. Y., & Tee, S. F. (2022) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2021.102932 · Cited by 24 · see citing works
Drug-Induced Movement Disorders
Rodnitzky, R. L. (2002) · Clinical Neuropharmacology · doi:10.1097/00002826-200205000-00004 · Cited by 24 · see citing works
“some level of improvement within 1 year (108).”
BackgroundDrug-induced movement disorders in children and adolescents
Rodnitzky, R. L. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.1.91 · Cited by 22 · see citing works
“In another study, only 2% who withdrew from neuroleptics had a significant recovery, but another 20% experienced some level of improvement within 1 year [111].”
BackgroundProgress in the Treatment of Tardive Dyskinesia: Theory and Practice
Feltner, D. E., & Hertzman, M. (1993) · Psychiatric Services · doi:10.1176/ps.44.1.25 · Cited by 23 · see citing works
Neuroleptics in the treatment of psychosis in late life: A rational approach
Mulsant, B. H., & Gershon, S. (1993) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.930081204 · Cited by 20 · see citing works
Pharmacological treatment of tardive dyskinesia: recent developments
Caroff, S. N., Campbell, E. C., & Carroll, B. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1358616 · Cited by 19 · see citing works
“However, evidence on the rate of improvement or remission from TD to be expected after drug reduction or cessation remains incomplete [14,60,61], and the risk of relapse in psychotic patients who require maintenance antipsychotic treatment is significant [13,20,62,63].”
BackgroundMovement disorders of the mouth: a review of the common phenomenologies
Ghadery, C. M., Kalia, L. V., & Connolly, B. S. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11299-1 · Cited by 18 · see citing works
“Nonetheless, only 2% of patients showed complete reversal after drug cessation [241, 242]; hence, total and permanent reversibility beyond the withdrawal stage is unusual.”
BackgroundAntipsychotic-Induced Tardive Dyskinesia
Cavallaro, R., & Smeraldi, E. (1995) · CNS Drugs · doi:10.2165/00023210-199504040-00005 · Cited by 18 · see citing works
Friedman, J. H. (2019) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000754 · Cited by 17 · see citing works
Drug-induced movement disorders in children
Rodnitzky, R. L. (2003) · Seminars in Pediatric Neurology · doi:10.1016/s1071-9091(02)00013-x · Cited by 17 · see citing works
Deuterium Tetrabenazine for Tardive Dyskinesia
Cummings, M. A., Proctor, G. J., & Stahl, S. M. (2018) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.cupr.010318 · Cited by 16 · see citing works
de Araújo, D. P., Camboim, T. G. M., Silva, A. P. M., Silva, C. D. F., de Sousa, R. C., Barbosa, M. D. A., de Oliveira, L. C., Cavalcanti, J. R. L. D. P., Lucena, E. E. D. S., & Gúzen, F. P. (2017) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2016-0307 · Cited by 15 · see citing works
Busanello, A., Leal, C. Q., Peroza, L. R., Röpke, J., Reis, E. D. M., de Freitas, C. M., Libardoni, M., Barbosa, N. V., & Fachinetto, R. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2335-4 · Cited by 14 · see citing works
Therapeutic targets in late-life psychoses: review of concepts and critical issues
Soares, J. C., & Gershon, S. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(97)00077-7 · Cited by 13 · see citing works
“An inverse correlation between age and improvement or disappearance of tardive dyskinesia when neuroleptics are stopped has been reported (Glazer et al., 1990; Smith and Baldessarini, 1980).”
BackgroundDeutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia
Dorfman, B. J., & Shahed, J. J. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1848548 · Cited by 13 · see citing works
McGrath, J. J., & Soares-Weiser, K. (1998) · doi:10.1002/14651858.cd000459 · Cited by 13 · see citing works
Lohr, J. B., Caligiuri, M. P., Edson, R., Lavori, P. W., Adler, L. A., Rotrosen, J., & HITZEMANN, R. J. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200204000-00014 · Cited by 12 · see citing works
DRUG-INDUCED MOVEMENT DISORDERS
Horn, S. S. (2004) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000293573.31991.8a · Cited by 10 · see citing works
Tseng, H.-C., Tsai, C.-C., Wang, M., Chang, K., Soung, H.-S., & Yang, C.-C. (2019) · The Chinese Journal of Physiology · doi:10.4103/cjp.cjp_8_19 · Cited by 10 · see citing works
Besag, F., Vasey, M. J., Salim, I., & Hollis, C. P. (2024) · Drug Safety · doi:10.1007/s40264-024-01446-0 · Cited by 9 · see citing works
“It has been suggested that younger adults (aged ≤ 55 years) may have a better prognosis than older individuals [99], but whether this might also apply to children is unclear.”
Valbenazine for Tardive Dyskinesia
Freudenreich, O., & Remington, G. J. (2017) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.ofgr.071717 · Cited by 9 · see citing works
Deutetrabenazine in the Treatment of Tardive Dyskinesia
Niemann, N., & Shahed, J. J. (2019) · Neurodegenerative Disease Management · doi:10.2217/nmt-2018-0042 · Cited by 9 · see citing works
Tardive Syndromes in the Elderly
Chou, K. L., & Friedman, J. H. (2006) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2006.06.008 · Cited by 9 · see citing works
Hyde, T. M., Apud, J. A., Fisher, W. C., & Egan, M. F. (2005) · doi:10.1002/9780470753217.ch9 · Cited by 9 · see citing works
Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia
El-Sayeh, H. G. G., Rathbone, J., Soares‐Weiser, K., & Bergman, H. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000458.pub3 · Cited by 8 · see citing works
Suzuki, T., & Uchida, H. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.08.024 · Cited by 8 · see citing works
Valbenazine for the treatment of tardive dyskinesia
Seeberger, L., & Hauser, R. A. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1353078 · Cited by 7 · see citing works
“Reported remission rates after discontinuation are 2–33% with long term follow-up [21,22].”
BackgroundAntipsychotikainduzierte tardive Syndrome
Fleischhacker, W. W., Hofer, A., Jagsch, C., Pirker, W., Psota, G., Rittmannsberger, H., & Seppi, K. (2016) · Neuropsychiatrie · doi:10.1007/s40211-016-0189-7 · Cited by 7 · see citing works
Fahn, S., Jankovic, J. J., & Hallett, M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-2369-4.00019-6 · Cited by 7 · see citing works
Drug-Induced Movement Disorders in Older Adults: An Overview for Clinical Practitioners
Detweiler, M. B., Kalafat, N., & Kim, K. Y. (2007) · The Consultant Pharmacist · doi:10.4140/tcp.n.2007.149 · Cited by 7 · see citing works
Revuelta, G. J., Cloud, L. J., Aia, P. G., & Factor, S. A. (2011) · doi:10.1002/9781444346183.ch21 · Cited by 7 · see citing works
Not So Hasty: The Effect of Tapering Speed on Relapse May Still Be Important
Horowitz, M. A., O’Neill, J., Berna, F. S., & Taylor, D. M. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf163 · Cited by 6 · see citing works
Tardive Dyskinesia: 21st Century May Bring New Treatments to a Forgotten Disorder
Rakesh, G., Muzyk, A. J., Szabo, S. T., Gupta, S., Pae, C., & Masand, P. S. (2017) · Annals of Clinical Psychiatry · doi:10.1177/104012371702900102 · Cited by 6 · see citing works
Medical and Surgical Treatment for Medication‐Induced Tremor: Case Report and Systematic Review
Amerika, W. E., van der Gaag, S., Mosch, A., Gaag, N. A. V. D., Hoffmann, C. F. E., Zutt, R., Marinus, J., & Contarino, M. F. (2022) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13463 · Cited by 5 · see citing works
Clozapine Treatment of Olanzapine-induced Tardive Dyskinesia: A Case Report
Sangroula, D., Virk, I., MOHAMMAD, W., & Kahn, D. A. (2017) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000203 · Cited by 5 · see citing works
NonParkinsonism Movement Disorders in the Elderly
Chen, J. J., & Lee, K. C. (2006) · The Consultant Pharmacist · doi:10.4140/tcp.n.2006.58 · Cited by 5 · see citing works
Nonaka, T., Horisawa, S., Kim, K.-S., Murakami, M., Nishitani, M., Kawamata, T., & Taira, T. (2025) · Journal of Movement Disorders · doi:10.14802/jmd.25164 · Cited by 4 · see citing works
Tardive Dyskinesia in Geriatric Patients
Ragheb, M. M., & Goldberg, R. J. (2006) · Aging Health · doi:10.2217/1745509x.2.5.833 · Cited by 4 · see citing works
“Glazer and colleagues reported that the most important predictors of chronic persistent TD included increased age and the presence of non-orofacial dyskinesia at baseline [66,67].”
BackgroundReversibility of Tardive Dyskinesia Syndrome
Viñuela, Á., & Kang, U. J. (2014) · Europe PMC (PubMed Central) · doi:10.7916/d86q1vxz · Cited by 4 · see citing works
“Nonetheless, the remission rate reported by the authors is strikingly similar to low rates noted by previous studies from decades ago, before the introduction of atypical antipsychotic drugs.(1,4,7) The pathophysiology of TS is not completely understood and there have been various proposed mechanisms, including upregu…”
Kessas, M., Creed, M. C., & Nóbrega, J. N. (2010) · Psychology & Neuroscience · doi:10.3922/j.psns.2010.2.012 · Cited by 4 · see citing works
Tardive Dyskinesia Remission during Risperidone Therapy
Santone, G., Cotani, P., Giuliani, S., & Marchesi, G. F. (1997) · Clinical Drug Investigation · doi:10.2165/00044011-199714060-00009 · Cited by 3 · see citing works
Jones, T., Jahan, I., & Zesiewicz, T. A. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781107588738.008 · Cited by 2 · see citing works
Fahn, S., Jankovic, J. J., Hallett, M., & Jenner, P. G. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-07941-2.50023-1 · Cited by 2 · see citing works
Karl, B., Bergman, H., Sayed, S. A. E., & Adams, C. E. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012986 · Cited by 2 · see citing works
Tardive Dyskinesia in Elderly Patients: An Update
Goldberg, R. J. (2002) · Journal of the American Medical Directors Association · doi:10.1097/00130535-200205000-00006 · Cited by 2 · see citing works
Tardive Dyskinesia in Elderly Patients: An Update
Goldberg, R. J. (2003) · Journal of the American Medical Directors Association · doi:10.1016/s1525-8610(04)70303-5 · Cited by 2 · see citing works
Psychopharmacists' Role in Neuroleptic Therapy a Pharmaceutical Care Approach
Lacro, J. P., Kodsi, A. B., & Gilbert, P. L. (1994) · Journal of Pharmacy Technology · doi:10.1177/875512259401000407 · Cited by 2 · see citing works
Synopsis of Chemical and Drug-Related Agents That Cause Movement Disorders
Korkmaz, Ş. A. (2025) · Springer eBooks · doi:10.1007/978-3-031-73368-0_126 · Cited by 1 · see citing works
Ge, J., Li, J., Ma, R., Tong, L., 薄奇静, & Zhang, Z. (2026) · Clinical Case Reports · doi:10.1002/ccr3.73194 · Cited by 1 · see citing works
Prävention und Behandlung von Antipsychotika-induzierten tardiven Dyskinesien
Erbe, S. (2018) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-0624-9368 · Cited by 1 · see citing works
Keeping up with the clinical advances: tardive dyskinesia
Elkurd, M. T., & Bahroo, L. B. (2019) · CNS Spectrums · doi:10.1017/s1092852919001263 · Cited by 1 · see citing works
Drug-induced tardive dyskinesia
Оstroumova, Т. М., Tolmacheva, V. A., Ostroumova, O. D., & Parfenov, V. A. (2020) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2020-1-81-86 · Cited by 1 · see citing works
Baumgärtner, J., Grohmann, R., Bleich, S., Glocker, C., Seifert, J., Toto, S., Rüther, E., Engel, R. R., & Stübner, S. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2021.1938213 · Cited by 1 · see citing works
“Glazer et al. (1990) showed complete remission of TD symptoms in 2% and improvement in 20% of patients.”
BackgroundCapellà, D., & Figueras, A. (1992) · Side effects of drugs annual · doi:10.1016/s0378-6080(05)80486-6 · Cited by 1 · see citing works
Editorials Reversibility of Tardive Dyskinesia Syndrome
Viñuela, Á., & Kang, U. J. (2015)
Fachinetto, R. (2006) · Americanae (AECID Library)
Espectro del Síndrome Tardío: Fenomenología, Diagnóstico y Tratamiento
Cárdenas, J. M., Arango, L. M., Gasca, R. A., & Zúñiga, M. A. (2021) · Revista Colombiana de Psiquiatría · doi:10.1016/j.rcp.2021.10.010
- Authors
- Glazer, W. M., Morgenstern, H., Schooler, N., Berkman, C. S., & Moore, D. C.
- Affiliations
- Yale University (US)
- University of California, Los Angeles (US)
- University of Pittsburgh (US)
- Columbia University (US)
- Corresponding author
- Glazer, William M.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 1990-10
- Volume
- 157
- Issue
- 4
- Pages
- 585-592
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2073219443
- Cited by
- 106
- References
- 41
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2022: 3 · 2021: 6 · 2020: 4 · 2019: 6 · 2018: 14 · 2017: 8 · 2016: 3 · 2015: 2 · 2014: 4 · 2013: 1
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The British Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH30929, MH52726)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- tardive dyskinesia, predictors of improvement, schizophrenia, chronic mental illness, schizoaffective disorder, neuroleptic dose, employment, age, movement disorders
- MeSH terms
- Adult, Dyskinesia, Drug-Induced, Female, Humans, Male, Middle Aged, Neurologic Examination, Prognosis, Prospective Studies, Psychiatric Status Rating Scales, Psychotic Disorders, Schizophrenia, Schizophrenic Psychology, Substance Withdrawal Syndrome, Antipsychotic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
